Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.
G2B-002, our flagship product, is a new therapeutic approach for pediatric tumors such as Diffuse Intrinsic Pontine Glioma (DIPG). Our peptide-shuttle carries the effective therapeutic drug to the brain to fight this devastating condition. Our approach combines oncology, rare disease and pediatrics.
Our novel delivery technology provides a non-invasive, non-antigenic, permeable, stable, soluble and receptor-specific way to transport drugs across the BBB and into the CNS. It has potential applications in a wide number of therapeutic areas and in transport through various biological barriers.
Gate2Brain envisions improving patients’ quality of life using a technology that provides superior drug transport efficacy with reduced side effects.
CDTI NEOTEC Program
This project is part of the CDTI’s NEOTEC program, which aims to promote the advancement and technological training of the Spanish industry with support for the creation and consolidation of technology-based companies.
A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies or knowledge developed from research activity. EBTs base their business strategy or activity on the intensive domain of scientific and technical knowledge.
The most relevant aspect in the proposals supported in this line must be a business strategy based on the development of technology (technology must be the competitive factor of differentiation of the company), based on the creation of lines of own R+D+i.
G2B-002 project by Gate2Brain is subsidized by the Centro para el Desarrollo Tecnológico Industrial (CDTI) and supported by the Ministry of Science and Innovation.